We use small files called cookies to help us improve your experience on this website and to provide services like web chat. We also use cookies to measure the effectiveness of public health campaigns and understand how people use the website.

Read our cookies policy to find out more about cookies and how we use them.

Best-value biological medicines

The Medicines Management Programme has identified best-value biological (BVB) medicines for TNF-α inhibitors under the High Tech Arrangement.

The MMP recommends the following BVB medicines for adalimumab and etanercept:

  •  Adalimumab:

              o   Citrate-containing: Idacio, Imraldi

              o   Citrate-free: Amgevita, Hulio

  •  Etanercept: Benepali

Clinicians should give due consideration to the prescription of these agents when prescribing a TNF-α inhibitor. Implementation of the BVB medicines will lead to significant savings for the health service, in the order of millions of euros.

Resources to support prescribing of the BVB medicines are located in the Related Files section below:

  • Questions and Answers for Healthcare Professionals.
  • MMP Product Information Sheets for Amgevita, Benepali, Hulio, Idacio and Imraldi.
  • Contact information for MMP support.
  • Contact information for patient support services for Amgevita, Benepali, Hulio, Idacio and Imraldi.
  • Templates for switching letters for Amgevita, Benepali, Hulio, Idacio and Imraldi.

From 1 February 2020, it is HSE policy that all adult patients who are commencing treatment with adalimumab or etanercept should be prescribed a best-value biological (BVB) medicine. Further information in relation to this can be found here.

Clinical Strategy and Programmes Division